Decreased Plasma Visfatin Concentrations in Women With Gestational Diabetes Mellitus
Tóm tắt
To test the hypothesis that plasma visfatin concentrations will he lower in women with gestational diabetes mellitus, we evaluated women with gestational diabetes mellitus and healthy pregnant women, and then correlated their plasma visfatin concentrations with body mass index (BMI) and various other parameters. A total of 40 women were evaluated: 20 women with gestational diabetes mellitus and 20 healthy pregnant women to serve as control subjects. Plasma visfatin concentrations were analyzed using an enzyme-linked immunosorbent assay. Plasma visfatin concentrations were significantly lower in the gestational diabetes mellitus group (9.4 ±3.8 ng/mL) than in the healthy control group (12.6 ±4.5 ng/mL) (P =. 023). A negative correlation was found between plasma visfatin concentrations and maternal age (r =–0.399, P =. 011), first trimester body weight (r = –0.350, P =. 027), and first trimester BMI (r =–0.336, P =. 034). Multiple linear regression analysis revealed that maternal age (P =. 011) and gestational diabetes mellitus /no gestational diabetes mellitus (P =. 044) were independently related to plasma visfatin concentrations. However, no relationship was found with either gestational age at the time of sampling or first trimester BML Our results show that there are decreased concentrations of plasma visfatin in gestational diabetes mellitus subjects and this may indicate that visfatin plays a role in the pathogenesis of gestational diabetes mellitus. However, further experiments are needed to clarify this role.
Tài liệu tham khảo
Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994; 14: 1431–7.
Hug C, Lodish HF. Medicine. Visfatin: A new adipokine. Science 2005;307: 366–7.
Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: A protein secreted by visceral fat that mimics the effects of insulin. Science 2005;307: 426–30.
American College of Obstetricians and Gynecologists Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 30, September 2001 (replaces Technical Bulletin Number 200, December 1994). Gestational diabetes. Obstet Gynecol 2001;98: 525–38.
Linne Y, Barkeling B, Rossner S. Natural course of gestational diabetes mellitus: Long term follow up of women in the SPAWN study. BJOG 2002;109: 1227–31.
Kitani T, Okuno S, Fujisawa H. Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor. FEBS Lett 2003;544: 74–8.
Ognjanovic S, Bao S, Yamamoto SY, Garibay-Tupas J, Samaî B, Bryant-Greenwood GD. Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. J Mol Endocrinol 2001;26: 107–17.
Krzyzanowska K, Krugluger W, Mittermayer F, et al. Increased visfatin concentrations in women with gestational diabetes mellitus. Clin Sci (Lond) 2006;110: 605–9.
Chen MP, Chung FM, Chang DM, et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing tactor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006;91: 295–9.
Rongvaux A, Shea RJ, Mulks MH, et al. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cy-tosolic enzyme involved in NAD biosynthesis. Eur J Immunol 2002;32: 3225–34.
Cinti S, Mitchell G, Barbatelli G, et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 2005;46: 2347–55.
Berndt J, Kloting N, Kralisch S, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005;54: 2911–6.